Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease

Neuroreport. 2001 Apr 17;12(5):1049-53. doi: 10.1097/00001756-200104170-00037.


In the present study the involvement of hydroxyl free radicals and nuclear factor-kappaB (NF-kappaB) activation was investigated in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease. MPTP (30 mg/kg, s.c.) produced a significant 2-fold increase in hydroxyl free radicals in the striatum of C57BL/6 mice determined by microdialysis in combination with the salicylate hydroxylation assay. Electrophoretic mobility shift assays did not detect NF-kappaB activation after MPTP treatment. Furthermore, p50-deficient mice showed only minor differences in striatal dopamine and metabolite levels as well as tyrosine hydroxylase immunoreactivity after MPTP administration in comparison to wildtype mice. We postulate that, although hydroxyl radical production was enhanced, NF-kappaB plays only a minor role in the MPTP model because neither neurochemical nor immunocytochemical parameters were altered in p50-deficient mice in comparison to controls.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine*
  • Animals
  • Biogenic Monoamines / metabolism
  • Biotransformation
  • Dopamine / metabolism
  • Dopamine Agents*
  • Electrophoresis
  • Female
  • Hydroxyl Radical
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Microdialysis
  • NF-kappa B / metabolism*
  • Oxidative Stress / physiology
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / metabolism*
  • Substantia Nigra / enzymology
  • Tyrosine 3-Monooxygenase / metabolism


  • Biogenic Monoamines
  • Dopamine Agents
  • NF-kappa B
  • Hydroxyl Radical
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Tyrosine 3-Monooxygenase
  • Dopamine